The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
Mueller, P. A., Yerkes, E., Bergstrom, P., Rosário, S., Hay, J., & Pamir, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-13040-4 · Cited by 13
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 14
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
He, J., Yang, M.-F., Song, C., Zhang, R., Yuan, S., Li, J., & Dou, K. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02203-3 · Cited by 13
Traditional and novel non-statin lipid-lowering drugs
Jain, P. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.003 · Cited by 15
Recent progress in gene therapy for familial hypercholesterolemia treatment
Luo, Y., Hou, Y., Zhao, W., & Yang, B. (2024) · iScience · doi:10.1016/j.isci.2024.110641 · Cited by 13
Fichtner, I., Macchi, C., Rizzuto, A. S., Carugo, S., Corsini, A., & Ruscica, M. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.09.004 · Cited by 13
Garcia, D. A., Pierre, A. F., Quirino, L., Acharya, G., Vasudevan, A., Pei, Y., Chung, E., Chang, J. Y. H., Lee, S., Endow, M., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.020 · Cited by 13
Shapiro, M. D., Haddad, T. M., WEINTRAUB, H. S., Baum, S. J., Abdul-Nour, K., Sarwat, S., Paluy, V., Boatwright, W., Browne, A., Ayaz, I., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.007 · Cited by 14
Self-citationWu, B., Zhao, H., Liu, C., Lu, H., Liu, R., Long, J., Zhang, Z., & Zeng, F. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1845517 · Cited by 13
Page, M. M., & Watts, G. F. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000842 · Cited by 13
Averna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 13
Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?
Afshar, M. S., Yazdan-Ashoori, S., Engert, J. C., & Thanassoulis, G. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.02.017 · Cited by 14
Coassin, S., Chemello, K., Khantalin, I., Forer, L., Döttelmayer, P., Schönherr, S., Grüneis, R., Chong-Hong-Fong, C., Nativel, B., Ramin‐Mangata, S., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003489 · Cited by 13
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Sourij, C., Aziz, F., Krappinger, S., Praschk, A., Metzner, T., Kojzar, H., Zirlik, A., Stojaković, T., Pätzold, D., von Lewinski, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115531 · Cited by 12
Association of Lipoprotein(a) with arterial stiffness: A Mendelian randomization study
Simistiras, A., Georgiopoulos, G. A., Delialis, D., Mavraganis, G., Oikonomou, E., Maneta, E., Loutos, C., Εvangelou, Ε., & Stamatelopoulos, K. S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14168 · Cited by 12
Pathological Mechanism and Treatment of Calcified Aortic Stenosis
Chen, S., Kong, X., & Zhang, J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000510 · Cited by 12
Manzato, M., Meeusen, J. W., Donato, L. J., Jaffe, A. S., & Vasile, V. C. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100886 · Cited by 11
Hoogeveen, R. C., Diffenderfer, M. R., Lim, E., Liu, C., Ikezaki, H., Guan, W., Tsai, M. Y., & Ballantyne, C. M. (2025) · Nutrients · doi:10.3390/nu17081324 · Cited by 12
Tackling cardiometabolic risk in the Asia Pacific region
Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 13
Liu, Y., Wang, W., Song, J., Zhang, K., Xu, B., Li, P., Shao, C., Yang, M. H., Chen, J., & Tang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.603922 · Cited by 12
Muscle Regeneration and RNA: New Perspectives for Ancient Molecules
Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021) · Cells · doi:10.3390/cells10102512 · Cited by 11
Drouin‐Chartier, J., Tremblay, A. J., Godbout, D., Gagnon, A., Clavel, M.-A. A., Clisson, M., Arsenault, B. J., Pîbarot, P., Larose, É., & Couture, P. (2020) · CJC Open · doi:10.1016/j.cjco.2020.09.010 · Cited by 16
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Cui, K., Wang, H., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, D., Song, C., Feng, L., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.807925 · Cited by 12
Fan, H. X., Kouvari, M., Mingrone, G., George, J., Papatheodoridis, G., Valenzuela‐Vallejo, L., Liu, Z., Chen, X., Zhang, T., & Mantzoros, C. S. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.018 · Cited by 12
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04179-4 · Cited by 12
Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions
Lan, N. S. R., Khan, Z. U., & Watts, G. F. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000976 · Cited by 11
Impact of High Lipoprotein(a) on Long‐Term Survival Following Coronary Artery Bypass Grafting
Yuan, S., Li, F., Zhang, H., Zeng, J., Su, X., Qu, J., Lin, S., Gu, D., Rao, C., Zhao, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031322 · Cited by 13
The Role of Lipoprotein(a) in Peripheral Artery Disease
Pavlatos, N., & Kalra, D. K. (2024) · Biomedicines · doi:10.3390/biomedicines12061229 · Cited by 14
Marrero, N., Jha, K. K., Razavi, A. C., Boakye, E., Anchouche, K., Dzaye, O. D. A., Budoff, M. J., Tsai, M. Y., Shah, S. J., Rotter, J. I., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016372 · Cited by 11
Zhao, Y., Wang, Z., Ji, R., Wang, Y., Zhang, Y., & Yu, K. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1383771 · Cited by 11
Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association study
Olmastroni, E., Katzmann, J. L., Galimberti, F., Laufs, U., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.01.021 · Cited by 11
Wang, L., Jiang, F., Sun, J., Zhao, J., He, Y., Gill, D., Burgess, S., Larsson, S. C., Yuan, S., & Li, X. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf020 · Cited by 11
Lipoprotein (a): A new target for pharmacological research and an option for treatment
Pirillo, A., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.021 · Cited by 14
RHPTree—Risk Hierarchical Pattern Tree for Scalable Long Pattern Mining
Liu, D., Li, Y., Baskett, W. I., Lin, D., & Shyu, C. (2022) · ACM Transactions on Knowledge Discovery from Data · doi:10.1145/3488380 · Cited by 11
Lipoprotein(a): Insights for the Practicing Clinician
Telyuk, P., Austin, D., Luvai, A., & Zaman, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133673 · Cited by 12
Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001011 · Cited by 11
Evans, P. C., Davidson, S. M., Wojta, J., Bäck, M., Bollini, S., Brittan, M., Catapano, A. L., Chaudhry, B., Cluitmans, M. J. M., Gnecchi, M., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac114 · Cited by 12
Milosavljević, M. N., Stefanović, S., & Pejčić, A. V. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001429 · Cited by 11
Reducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 11
Gonen, A., Yang, X., Yeang, C., Alekseeva, E. A., Koschinsky, M. L., Witztum, J. L., Boffa, M. B., & Tsimikas, S. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000830 · Cited by 11
Self-citationNicholls, S. J., & Bubb, K. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01528-w · Cited by 12
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
Catapano, A. L., Ray, K. K., & Tokgözoğlu, L. S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.021 · Cited by 11
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12
Potential of muvalaplin as a lipoprotein(a) inhibitor
Hooper, A. J., Fernando, P. M. S., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2302592 · Cited by 11
Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression
Zhang, C., Zhang, Y., Yu, Y., Zhou, M., Zhang, J., Fu, K., & Li, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177879 · Cited by 10
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 11
Lipoprotein(a)-lowering therapies: a promising future
Zhang, J., Návar, A. M., & Tokgözoğlu, L. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag092 · Cited by 13
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 11
Lipoprotein(a) and Oxidized Phospholipids
Rader, D. J., & Bajaj, A. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.051 · Cited by 10
Anagnostis, P. G., Antza, C., Florentin, M., & Kotsis, V. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97845 · Cited by 10
Nakamura, N., Sakai, K., Torii, S., Aoki, Y., Turcotte‐Gosselin, F., Fujinuma, K., Ohwaki, A., Aihara, K., Noda, S., Miyamoto, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.011 · Cited by 10
Thomas, P. E., Vedel‐Krogh, S., & Kamstrup, P. R. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001168 · Cited by 11
Nomura, S. J. O., Bhatia, H. S., Garg, P. K., Karger, A. B., Guan, W., Cao, J., Shapiro, M. D., & Tsai, M. Y. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100903 · Cited by 10
Self-citationManagement of dyslipidaemia in patients with comorbidities—facing the challenge
Frühwald, L., Fasching, P., Dobrev, D., Kaski, J. C., Borghi, C., Waßmann, S., Huber, K., Semb, A. G., Agewall, S., & Drexel, H. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae095 · Cited by 10
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature
Sheashaa, H., Mousa, H., Abbas, M. T., Farina, J., Awad, K., Pereyra, M., Scalia, I. G., Ali, N. B., Javadi, N., Bismee, N. N., et al. (2025) · Biomolecules · doi:10.3390/biom15020162 · Cited by 11
Aminorroaya, A., Dhingra, L. S., Oikonomou, E. K., & Khera, R. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004632 · Cited by 10
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 11
Residual lipoprotein(a)-associated risk in patients with stroke or transient ischemic attack
Hoshino, T., Mizuno, T., Arai, S., Hosoya, M., Wako, S., Takahashi, S., Oshima, R., Higuchi, E., Ishizuka, K., Toi, S., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119231 · Cited by 10
Global lipoprotein (a) testing trends from 2015 to 2023
Hanif, M., Khan, L. A., Kulkarni, A., Bhatia, H. S., Wilkinson, M. J., Rashid, A. M., Chew, N., Banerjee, S., Butler, J., Shapiro, M. D., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.06.010 · Cited by 10
Self-citationLipoprotein(a) and risk of dementia: findings from three cohort studies
Thomas, P. E., Vedel‐Krogh, S., Nielsen, S. F., Nordestgaard, B. G., Frikke‐Schmidt, R., & Kamstrup, P. R. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf465 · Cited by 10
Self-citationNordestgaard, A. T., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I.-M. M., Buring, J. E., & Ridker, P. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00306-0 · Cited by 10
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Hsieh, G., Rizk, T., Berman, A. N., Biery, D. W., & Blankstein, R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000901 · Cited by 10
Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction
Miñana, G., Cordero, A., Fácila, L., Fernández‐Cisnal, A., Valero, E., Carratalá, A., Navarro, J., Llergo, J. T., Fernández-Olmo, R., Castro, A., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.10.028 · Cited by 10
Tao, Y., Wang, Y., Yin, Y., Zhang, K., Gong, Y., Ying, H., & Jiang, R. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02163-4 · Cited by 11
Partridge, W., Xia, S., Kwoh, T. J., Bhanot, S., Geary, R. S., & Baker, B. F. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0917 · Cited by 10
Self-citationThe Potential Clinical Benefit of Lowering Lipoprotein(a)
Ference, B. A. (2022) · JAMA · doi:10.1001/jama.2022.5333 · Cited by 10
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions
de Boer, L. M., Wiegman, A., Swerdlow, D. I., Kastelein, J. J. P., & Hutten, B. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2118522 · Cited by 10
Tsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 9
Stoll, F., Seidel-Glätzer, A., Burghaus, I., Göring, O., Sauter, M., Rose, P. W., Daniel, V., Haag, M., Schwab, M. G., Riffel, J. H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415924 · Cited by 10
Lipoprotein(a) and CT Angiography
Tsimikas, S., & Narula, J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.015 · Cited by 10
Self-citationValue of Genetic Testing for Lipoprotein(a) Variants
Langsted, A., & Nordestgaard, B. G. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003737 · Cited by 10
Self-citationChen, Y., Liang, L., Wu, C., Cao, Z., Xia, L., Meng, J., & Zuo, W. (2022) · DNA and Cell Biology · doi:10.1089/dna.2022.0278 · Cited by 9
Ancestral diversity in lipoprotein(a) studies helps address evidence gaps
Lee, M. P., Dimos, S. F., Raffield, L. M., Wang, Z., Ballou, A. F., Downie, C. G., Arehart, C. H., Correa, A., de Vries, P. S., Du, Z., et al. (2023) · Open Heart · doi:10.1136/openhrt-2023-002382 · Cited by 9
Qi, Y., Duan, Y., Deng, Q., Yang, N., Sun, J., Li, J., Hu, P., Liu, J., & Liu, J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033488 · Cited by 8
Afzal, Z., Cao, H., Chaudhary, M. A., Chigurupati, H. D., Neppala, S., Alruwaili, W., Awad, M. A., Sandesara, D., Siddique, M., Farman, A., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102586 · Cited by 9
Wang, Z., Tang, J., Shi, Q., Fang, L., Liu, N., & Zhang, J. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2454975 · Cited by 9
Emerging Roles of Long Non‐Coding RNAs in Cardiovascular Diseases
Kong, X., Li, F., & Wang, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70453 · Cited by 11
Girard, A. S., Paulin, A., Manikpurage, H. D., Lajeunesse, E., Clavel, M.-A. A., Pîbarot, P., Krege, J. H., Mathieu, P., Thériault, S., & Arsenault, B. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038955 · Cited by 9
Nordestgaard, A. G., Chasman, D. I., Moorthy, M. V., Kraaijenhof, J. M., Cook, N. R., Lee, I.-M. M., Buring, J. E., & Ridker, P. M. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5043 · Cited by 10
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity
Kille, A., Nührenberg, T. G., Franke, K., Valina, C. M., Leibundgut, G., Tsimikas, S., Neumann, F., & Hochholzer, W. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02515-2 · Cited by 9
Self-citationRNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 10
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Lipoprotein(a): a Case for Universal Screening in Youth
Alankar, A., Brar, P. C., & Kohn, B. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01120-3 · Cited by 9
Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors
Chemello, K., Gallo, A., Guédon, A. F., Techer, R., Croyal, M., Swietek, M. J., Meilhac, O., Amarenco, P., & Lambert, G. C. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100557 · Cited by 11
Diederiks, N. M., Ruhaak, L. R., Romijn, F. P. H. T. M., Pieterse, M., Smit, N. P. M., & Cobbaert, C. M. (2024) · Clinical Proteomics · doi:10.1186/s12014-023-09446-5 · Cited by 9
All we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 9
Recent advances and emerging therapies in management of dyslipidemias
Pulipati, V. P., & Davidson, M. H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.08.007 · Cited by 9
Chakraborty, A., Pang, J., Chan, D. C., Barnett, W., Woodward, A. M., Vorster, M., & Watts, G. F. (2021) · Clinical Cardiology · doi:10.1002/clc.23607 · Cited by 9
Wu, H., Luan, J., Forgetta, V., Engert, J. C., Thanassoulis, G., Mooser, V., Wareham, N. J., Langenberg, C., & Richards, J. B. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003312 · Cited by 9
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease
Rader, D. J. (2025) · New England Journal of Medicine · doi:10.1056/nejme2503824 · Cited by 9
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
